Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Service d'aide à la décision clinique

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    2 0 0 0

Annales de Dermatologie et de Vénéréologie
Volume 139, n° 10
pages 693-694 (octobre 2012)
Doi : 10.1016/j.annder.2012.05.030
Received : 9 May 2012 ;  accepted : 22 May 2012
De nouveaux espoirs dans le traitement du mélanome métastatique ?
New hope in metastatic melanoma treatment?

B. Guillot
Département de dermatologie, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier cedex 5, France 

 Commentaire de : Improved survival with ipilimumab in patients with metastatic melanoma Hodi FS, O’Day SJ, McDermott DF, Weber RW et al. N Engl J Med 2010;363:711–2.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation Chapman PB, Hauschild A, Rpbert C, Haanen JB et al. N Engl J Med 2011;364:2507–16.

© 2012  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline